Clinical Trials Details

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib vs. Sotorasib or Adagrasib in Patients with Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer

IRB Protocol Number

BO45217

Clinical Trial Categories

• Lung Cancer

Contact

Clinical Trials at 910-715-2200

How to Participate

Eligibility:

Men or women, ages 18 and older, with locally advanced or metastatic NSCLC not amenable to treatment with surgical resection or combined chemoradiation, positive for KRAS p.G12C mutation, with disease progression during or after treatment with at least one prior systemic therapy but no more than three lines of prior systemic therapy in the advanced or metastatic setting.